You are here:  Home | About | Healthcare Analytics
Healthcare Analytics

Recent advances in medical research have opened up a world of new treatment options for patients with complex conditions and diseases attending Specialist Medical Clinics.

 

A wide-range of methods, pharmaceuticals and biologics are now available to consultants for treating patients with complex conditions and diseases. This provides the possibility of radically improving the lives of many patients in many different clinical specialisms. As a result, clinicians are increasingly reliant on the analysis of large amounts of diverse data from genomic studies, system biology and biomedical analysis in order to enhance the understanding of diseases and improve clinical decision-making - in this respect, there is a need for advanced healthcare analytics solutions.

 

Advanced New Treatments

A major new advance in the treatment of patients with complex diseases and conditions is the introduction of "Biologics". "Biologics" can be used to refer to a wide range of biological products in medicine. In most cases, however, the term "biologics" is used more restrictively for a class of therapeutics (either approved or in development) that are produced by means of biological processes involving recombinant DNA technology.

 

"A biologic medical product, also known as a biological product, or more simply as a biologic or biological, is a medicinal product such as a vaccine, blood or blood component, allergenic, somatic cell, gene therapy, tissue, recombinant therapeutic protein, or living cells that are used as therapeutics to treat diseases. Biologics are created by biologic processes, rather than being chemically synthesized. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. Biologics are isolated from a variety of natural sources - human, animal, or microorganism - and may be produced by biotechnology methods and other technologies. Gene-based and cellular biologics, for example, often are at the forefront of biomedical research, and may be used to treat a variety of medical conditions for which no other treatments are available." Taken from Wikipedia.

 

 

Clinical Issues and Economic Implications

Biologics as a class of medications in this narrower sense have had a profound impact on many medical fields, primarily rheumatology and oncology, but also cardiology, dermatology, gastroenterology, neurology, and others. In most of these disciplines, biologics have added major therapeutic options for the treatment of many diseases, including some for which no effective therapies were available, and others where previously existing therapies were clearly inadequate.

 

The advent of biologic therapeutics has also raised complex regulatory issues (see below), and significant pharmaco-economic concerns, because the cost for biologic therapies has been dramatically higher than for conventional (pharmacological) medications. This factor has been particularly relevant since many biological medications are used for the treatment of chronic diseases, such as rheumatoid arthritis or inflammatory bowel disease, or for the treatment of otherwise untreatable cancer during the remainder of life.

 

 

Need for Advanced New Systems

Research from medical discussions forums, clinical focus groups and published reports from NICE and Scottish Medications Consortium (SMC) have identified a distinct need for clinically-usable solutions to systematically record and manage clinical data to measure and evaluate patient treatment-outcomes in order to optimise expensive clinical treatment processes.

 

Furthermore, pressures from UK and Scottish government health ministers and local authorities and NHS trusts, have put significant pressures on NHS budgets and clinical teams to become more clinically effective and departments and hospitals more economically efficient. As such there is a need for "Advanced New Systems" to provide a cost-effective framework for meeting stringent regulatory requirements, improving patient treatment outcomes, optimising the cost-benefits of delivery of advanced and complex treatments, while reducing many major overhead costs of service provision.